
#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx
Links:
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppress…
https://bit.ly/3ogW4fm
09-11-2021